Case File
efta-efta00700584DOJ Data Set 9OtherDS9 Document EFTA00700584
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00700584
Pages
2
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
To: Jamie Heywood .1
Subject: Jeffery, investing, and aobiome
Date: Thu, 17 Jul 2014 14:43:12 +0000
Jeffrey Epstein <[email protected]>
Jamie -
Jeffery would like to see a business plan. He is very interested in the company, and in the possibility of
investing, but needs to see more info.
Jeffery, the investor call info is below, including a link to prepared documents for the investor call.
Will leave it to the two of you to determine if you want to chat 1:1.
Best,
Linda
Jamie - I'll be over there today with Jasmine. Thank you! Excited to try the product!
16-Jul-14
Hello Linda
On Monday 2I-July at 3PM EST, I am hosting a conference call to introduce AOBiome to potential investors. I wanted to invite you to join
this call as it will provide a very comprehensive picture of the AOBiome's past, present, and future. While a small part of the presentation is
geared toward investors, the vast majority of the call is generic and something! think you would find interesting.
The eMail that our CFO Joe Grimm is sending out reads...
Hello,
We are delighted to invite you to a presentation highlighting AOBiome's recent and exciting developments and
longer-term investment growth prospects. In addition, we will update existing investors on our recently initiated
Series B fund raising effort where we are seeking to raise $4 million at $1.50 per share from a select group of
new "valued-added" individual investors and existing investors who would like to top-off or participate to a
lesser degree. Initial interest from new investors has been exceptionally strong and we anticipate closing the
round in several weeks.
On the call will be our founders, Jamie Heywood, David Whitlock and Lenny Barshack; and our management
team, including Spiros Jamas (CEO), Larry Weiss (Chief Medical Officer), Jasmina Aganovic (Head of
Consumer) and Joe Grimm (CFO). The call is scheduled for this Monday, July 21, 2014 from 3:00 pm to 4:30
pm EST.
Please use the following call-in information:
Monday, July 21, 2014 from 3:00 pm to 4:30 pm EST.
Telephone number: 712-432-3100
Pass code: 113569
The Powerpoint for the presentation, along with other information can be found at: DropBox
AOBiome is The Leading Skin Microbiome Company and we are leveraging our patent portfolio and scientific
EFTA00700584
knowhow to address growing unmet medical needs in the therapeutic and consumer markets. Therapeutically, we
are developing first in class pharmaceutical products for acne, eczema and diabetic ulcers. These unique
formulations build on our AO+ Mist consumer experience and safety database, promising scientific efficacy
studies in cells and animals, and ten years of microbe strain selection and development. We expect to initiate
clinical studies in 2015 in at least two therapeutic indications.
As Lenny undoubtedly mentioned, our lead consumer product, AO+ Mist, is a proprietary, clinically tested
beneficial microbe (aka "good bacteria") for improving skin appearance and vibrancy. We believe this product
has much potential in several consumer categories and while we have a keen interest in growing the brand and
introducing "biome friendly" soaps and shampoos, you should know we are in discussions with major consumer
health companies, including Unilever, P&G and J&J.
The response to the New York Times Magazine "No Soap No Shampoo" article has been terrific in the number
of emails we've received (>15,000). We have continued to get media coverage from others such as Good
Morning America, NPR and the London Sunday Times. In fact the enthusiasm for AO+ Mist has been far beyond
our expectations largely due to unanticipated high demand from holistically-minded consumers. An analysis of
our emails puts this group slightly ahead of those seeking to improve ongoing skin issues and those wanting
healthier looking skin. This has been confirmed in discussions with consumer products companies — there is a
growing backlash against anti-microbial soaps and the effects of harsh surfactants on the skin microbiome—and
is unlikely to be just a fad. As a result, we believe that the branding and messaging we are developing will
position us to capture a much broader consumer market.
Thank you for your interest and we hope you can join our call,
Joe
Important links when you have time
"No Soap No Shampoo" Article by Julia Scott featured in the New York Times Magazine
Good Morning America, TV segment featuring AO+ Mist and Julia Scott
NPR "On Point" radio broadcast featuring Jamie Heywood and Julia Scott
London Sunday Times featuring our scientific founder, David Whitlock, and AO+ Mist
AOBiome.com
Joseph Grimm
CFO
AOBiome LLC
EFTA00700585
Technical Artifacts (3)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.